Results 21 to 30 of about 35,674 (297)

Leveraging pharmacy partnerships and Grant funding to improve access to medications for opioid use disorder [PDF]

Exploratory Research in Clinical and Social Pharmacy
Background: Increased availability and access to FDA-approved medications for opioid use disorder (MOUD) can improve efforts to address the ongoing opioid public health crisis.
John M. Vasko, Erin Shirley Orey, Carolanne Wartman, James K. Rowlett, Jefferson D. Parker, Donna M. Platt, Julie A. Schumacher   +6 more
doaj   +2 more sources

271 Evaluation of treatment for opioid use disorder across North Carolina: a study protocol

Journal of Clinical and Translational Science
OBJECTIVES/GOALS: Our objectives are to: 1) characterize opioid treatment providers in North Carolina according to payment methods accepted and ability to provide medications for opioid use disorder and 2) use geomapping technology to characterize ...
Rachel Lynn Graves, Janine Short, Erin W. Barnes, Jason Stopyra   +3 more
doaj   +2 more sources

Receipt of medications for opioid use disorders among veterans by race/ethnicity and legal involvement: an observational study of electronic health records

Health & Justice
Background The Veterans Health Administration has made strides to improve access to medications for opioid use disorder overall. However, quality improvement methods to assess treatment gaps may not sufficiently detect differences in medication access by
Andrea K. Finlay, Ekaterina Pivovarova, Mengfei Yu, Christine Timko, Ingrid A. Binswanger, David Smelson, Emmeline Taylor, Alex H. S. Harris   +7 more
doaj   +2 more sources

Concurrent opioid and alcohol withdrawal management [PDF]

Mental Health Clinician, 2023
Concurrent alcohol and opioid withdrawal syndrome is a common and challenging clinical scenario with little published evidence or guidance to inform pharmacotherapy strategies.
Michelle Colvard, PharmD, BCPP
doaj   +1 more source

Medication Treatment of Opioid Use Disorder [PDF]

Biological Psychiatry, 2020
Opioid use disorder (OUD) is a chronic, relapsing condition, often associated with legal, interpersonal, and employment problems. Medications demonstrated to be effective for OUD are methadone (a full opioid agonist), buprenorphine (a partial agonist), and naltrexone (an opioid antagonist).
James Bell, John Strang
openaire   +5 more sources

Medications for opioid use disorder shape immune responses during chronic HIV infection [PDF]

Cell Reports Medicine
Summary: People living with HIV (PLWHs) have higher risk of opioid use disorder (OUD). Whether medications for opioid use disorder (MOUDs) change immune responses in HIV infection is unknown.
Jack A. Collora, Savannah F. Steinhauser, Timothy C. Davenport, Daniel C. Lin, Amare Eshetu, Samana Zeidi, Rachel Kim, Cynthia Frank, Yuval Kluger, Sandra A. Springer, Ya-Chi Ho   +10 more
doaj   +2 more sources

The Evolving Medicolegal Precedent for Medications for Opioid Use Disorder in U.S. Jails and Prisons. [PDF]

, 2021
Medications for opioid use disorder, also known as medication-assisted treatment (MAT), are critical in the treatment of opioid use disorder. Historically, inmates with opioid use disorder in U.S.
McNiel, Dale E, Toyoshima, Takeo, Binder, Renée, Schonfeld, Ariel   +3 more
core   +1 more source

Six-month outcomes of the HOPE smartphone application designed to support treatment with medications for opioid use disorder and piloted during an early statewide COVID-19 lockdown

Addiction Science & Clinical Practice, 2022
Background Morbidity and mortality related to opioid use disorder (OUD) in the U.S. is at an all-time high. Innovative approaches are needed to address gaps in retention in treatment with medications for opioid use disorder (MOUD). Mobile health (mHealth)
Jacqueline Hodges, Marika Waselewski, William Harrington, Taylor Franklin, Kelly Schorling, Jacqueline Huynh, Alexa Tabackman, Kori Otero, Karen Ingersoll, Nassima Ait-Daoud Tiouririne, Tabor Flickinger, Rebecca Dillingham   +11 more
doaj   +1 more source

Development and implementation of a physician-pharmacist collaborative practice model for provision and management of buprenorphine/naloxone [PDF]

Mental Health Clinician, 2021
Introduction: Physician-pharmacist collaborative practice models (PPCPM) decrease barriers and increase access to medications for opioid use disorder (MOUD) but are not routine in practice. The purpose of this quality improvement initiative is to develop
Lindsay M. Mailloux, PharmD, Matthew T. Haas, PharmD, BCPP, BCPS, Janel M. Larew, PharmD, BCPS, Beth M. DeJongh, PharmD, BCPP, BCPS   +3 more
doaj   +1 more source

Medications for management of opioid use disorder

American Journal of Health-System Pharmacy, 2019
Abstract Purpose The use of buprenorphine, methadone, and long-acting naltrexone for treatment of opioid use disorder (OUD) is discussed, including a review of current literature detailing treatment approaches and action steps to optimize treatment in acute care and office-based settings.
Jennifer L, Koehl, David E, Zimmerman, Patrick J, Bridgeman   +2 more
openaire   +2 more sources